Use of pentoxifylline in membranous nephropathy

Urinary TNF-α excretion correlates with proteinuria in patients with membranous nephropathy (MGN). Pentoxifylline suppresses or reduces the production of TNF-α. Between April, 1999 and August, 2000, we did a single-centre, prospective, pilot study to assess the effects of pentoxifylline (1200 mg/day...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lancet (British edition) 2001-05, Vol.357 (9269), p.1672-1673
Hauptverfasser:	Ducloux, Didier, Bresson-Vautrin, Catherine, Chalopin, Jean-Marc
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Biological and medical sciences Clinical trials Correlation analysis Disease Drug therapy Drug Therapy, Combination Female Follow-Up Studies Glomerulonephritis, Membranous - drug therapy Glomerulonephritis, Membranous - immunology Humans Immune system Kidney Function Tests Male Medical sciences Mortality Nephrotic Syndrome - drug therapy Nephrotic Syndrome - immunology Pentoxifylline - adverse effects Pentoxifylline - therapeutic use Pharmacology. Drug treatments Pilot Projects Prospective Studies Proteinuria - drug therapy Proteinuria - immunology Tumor Necrosis Factor-alpha - urine Urinary system
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Urinary TNF-α excretion correlates with proteinuria in patients with membranous nephropathy (MGN). Pentoxifylline suppresses or reduces the production of TNF-α. Between April, 1999 and August, 2000, we did a single-centre, prospective, pilot study to assess the effects of pentoxifylline (1200 mg/day) on proteinuria in patients with idiopathic MGN. Ten patients were included and treated for 6 months. Pentoxifylline significantly decreased proteinuria from 11g/day [range 4·6–27] to 1·8 (0–10·9); p=0·001). Pentoxifylline may be a safe and effective adjunct to steroids and immunosuppressants in patients with MGN.
ISSN:	0140-6736 1474-547X
DOI:	10.1016/S0140-6736(00)04830-3